BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

...toxic. Both therapies are in Phase I testing for solid tumors and lymphomas. Codiak’s preclinical exoSTING...
...surface protein. President and CEO Douglas Williams told BioCentury many of the mDCs targeted by exoSTING...
...Data presented at the 2018 SITC meeting showed that in a mouse model of melanoma, exoSTING...
BioCentury | Nov 6, 2018
Preclinical News

Codiak’s exosomes could offer new tack to STING agonism

...BioSciences Inc. (Cambridge, Mass.) on Tuesday provided a first glimpse of preclinical data for its exoSTING...
...than compounds currently being tested in the clinic, President and CEO Douglas Williams told BioCentury. exoSTING...
...molecule STING agonist payload to dendritic cells in the tumor microenvironment. Dendritic cells activated by exoSTING...
Items per page:
1 - 2 of 2